Cytek Biosciences, Inc. CTKB
5.92 USD +0.22 (+3.86%)
Regular-session close
5.92 0.00 0.00%
After hours · Nov 18, 4:01 PM ET
5.62 Day range 5.98
3.31 52-week range 6.34
- YTD
- +17.23%
- 1 year
- +7.05%
News
globenewswire.com Cytek Biosciences to Participate in Upcoming Investor Conferences FREMONT, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the…benzinga.com Stephens & Co. Maintains Overweight on Cytek Biosciences, Raises Price Target to $7 Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and raises the price target from $6 to $7.
globenewswire.com Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug…
seekingalpha.com Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
zacks.com Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.01 per share a year ago.
marketbeat.com Cytek Biosciences Q3 Earnings Call Highlights Cytek Biosciences NASDAQ: CTKB reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, as growth in the U.S. and demand for its high-end instruments helped offset weakness in…
benzinga.com Cytek Biosciences Q3 2026 Earnings Call Transcript Cytek Biosciences (NASDAQ:CTKB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Cytek Biosciences Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $53.229M Beat $52.800M Estimate Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 25 percent decrease over losses of…
benzinga.com Cytek Biosciences Narrows FY2026 Sales Guidance from $207.000M-$212.000M to $208.000M-$211.000M vs $209.415M Est Cytek Biosciences (NASDAQ:CTKB) narrows FY2026 sales outlook from $207.000 million-$212.000 million to $208.000 million-$211.000 million vs $209.415 million estimate.
globenewswire.com Cytek Biosciences Reports Third Quarter 2026 Financial Results FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results…
globenewswire.com Cytek Biosciences to Participate in Upcoming Investor Conferences FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the…
zacks.com Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter…
defenseworld.net Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month High – Here’s What Happened Cytek Biosciences, Inc. (NASDAQ: CTKB - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $6.21 and last traded at $5.9950, with a volume of…
defenseworld.net 1,315,332 Shares in Cytek Biosciences, Inc. $CTKB Acquired by Bank of America Corp DE Bank of America Corp DE purchased a new position in shares of Cytek Biosciences, Inc. (NASDAQ: CTKB) during the undefined quarter, according to the company in its most recent filing with the…
globenewswire.com Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.
defenseworld.net Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB) Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies…
zacks.com Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock? Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
seekingalpha.com Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry FREMONT, Calif., and HAMBURG, Germany, Sept.
globenewswire.com Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow…
defenseworld.net Deutsche Bank AG Makes New $496,000 Investment in Cytek Biosciences, Inc. $CTKB Deutsche Bank AG bought a new position in Cytek Biosciences, Inc. (NASDAQ: CTKB) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund…
globenewswire.com Cytek Biosciences to Participate in Upcoming Investor Conferences FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the…
globenewswire.com Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced…
